Compare iShares MSCI Japan ETF (EWJ) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs IDEXX Laboratories, Inc. — how do they compare? iShares MSCI Japan ETF trades at $97.88 (market cap $23.87B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and iShares MSCI Japan ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 56 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| EWJ | IDXX | |
|---|---|---|
Market Cap | $23.87B | $40.43B |
Volume | 5,412,820 | 692,164 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $766.68 |
52-Week Low | $78.36 | $504.70 |
Typical Hold Time | 56 Days | 46 Days |
Enterprise Value | — | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.86, down 0.47% today amid mixed technical signals. The overall technical picture is neutral with bullish moving averages but neutral oscillators, suggesting consolidation near key support at $97. Recent news highlights Japan's monetary policy shifts and regional market volatility, with the Bank of Japan's rate hike cycle creating both opportunities and challenges for Japanese equities.
The outlook for EWJ remains balanced with potential upside from Japan's economic reforms and AI sector growth, but risks include yen volatility and rising global bond yields. Investor sentiment is cautiously optimistic as international ETFs outperform US markets, though Japanese fiscal stimulus concerns and currency pressures warrant close monitoring for volatility spikes.
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
